Streetwise Reports (06/19/2026)
Traws Pharma, Inc.'s (TRAW:NASDAQ) bird flu antiviral hits a U.K. regulatory hurdle, delaying its Phase 2a study and prompting an analyst downgrade from Buy to Neutral. Streetwise Reports (06/19/2026)
Rezolute Inc. (RZLT:NASDAQ) presented promising data at ENDO 2026, with analysts eyeing big gains and a "Buy" rating as Phase 3 study results loom in the second half of 2026. Streetwise Reports (06/19/2026)
Sernova Biotherapeutics leverages its Cell Pouch technology and recent FDA orphan drug designation to address type 1 and type 3c diabetes amid a growing global market, supported by improved financial stability for retail investors. Streetwise Reports (06/18/2026)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) announces it has been granted orphan drug designation for autologous islet transplantation (AIT) for preventing diabetes following a total pancreatectomy. Streetwise Reports (06/18/2026)
Explore how enGene Therapeutics is advancing its novel gene therapy, Detalimogene, for bladder cancer within a growing oncology market, including clinical progress, financial strength, and upcoming catalysts for investors. Streetwise Reports (06/17/2026)
enGene Therapeutics Inc. (ENGN:NASDAQ) shared Q2 results and LEGEND trial updates for detalimogene, its non-muscle invasive bladder cancer therapy, as analysts waver on stock. Streetwise Reports (06/17/2026)
Teva Pharmaceutical Industries reports robust first-quarter revenue growth from AUSTEDO and specialty products while closing the Emalex acquisition and advancing multiple late-stage programs in neuroscience, immunology, and respiratory diseases for retail investors. 
Streetwise Key Charts
